Valuation: Prenetics Global Limited

Market Cap 314M 273M 254M 233M 440M 29.94B 447M 2.99B 1.17B 14.91B 1.18B 1.15B 49.99B P/E 2026 *
-6.35x
P/E 2027 * -64.8x
Enterprise Value 314M 273M 254M 233M 440M 29.94B 447M 2.99B 1.17B 14.91B 1.18B 1.15B 49.99B EV / Sales 2026 *
1.45x
EV / Sales 2027 * 0.83x
Free-Float
85.05%
Yield 2026 *
-
Yield 2027 * -
1 day-3.12%
1 week-0.53%
1 month+4.19%
3 months+9.52%
6 months-2.38%
Current year+18.35%
1 week 17.5
Extreme 17.5
20.69
1 month 15.91
Extreme 15.91
22.75
Current year 14
Extreme 14
23.63
1 year 7.18
Extreme 7.175
23.63
3 years 2.85
Extreme 2.85
23.63
5 years 2.85
Extreme 2.85
131.25
10 years 2.85
Extreme 2.85
131.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 52 01/01/2014
Chief Executive Officer 47 01/01/2014
Director of Finance/CFO 41 01/01/2018
Director TitleAgeSince
Chairman 47 01/01/2014
Director/Board Member 38 -
Director/Board Member 60 13/06/2024
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Other

CFO of IM8 (US) LLC

56,851 0.3729%
04/07/26 Fiscal year

Director

4,000 0.0262%
Change 5-day change 1-year change 3-year change Capi.($)
-3.12%-0.53%+133.00%+80.10% 314M
+0.09%+2.56%-16.96%-4.37% 183B
-0.37%+2.62%-4.42%-2.61% 109B
-0.29%+0.47%+7.97%+64.64% 60.57B
+3.50%+0.47%+41.00%+46.44% 51.8B
+0.10%+5.92%-6.10%-40.54% 45.64B
+0.41%+1.37% - - 33.22B
+11.95%+16.65%+5.26%-31.60% 31.49B
+0.40%+3.89%+42.51%-8.26% 24B
-1.22%+6.69%+0.67%+1.96% 22.26B
Average +1.14%+4.32%+22.55%+11.75% 56.15B
Weighted average by Cap. +0.92%+3.49%-0.03%+4.28%

Financials

2026 *2027 *
Net sales 216M 188M 175M 160M 303M 20.62B 308M 2.06B 809M 10.27B 811M 793M 34.42B 378M 328M 305M 280M 530M 36.04B 538M 3.6B 1.41B 17.94B 1.42B 1.39B 60.16B
Net income -69.45M -60.37M -56.19M -51.59M -97.43M -6.63B -98.94M -662M -260M -3.3B -261M -255M -11.07B -5.67M -4.93M -4.59M -4.21M -7.95M -541M -8.08M -54.08M -21.23M -269M -21.3M -20.83M -904M
Net Debt - -
Logo Prenetics Global Limited
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
Employees
98
Date Price Change Volume
31/07/26 $18.64 -3.12% 42,540
30/07/26 $19.24 +6.77% 69,981
29/07/26 $18.02 -1.31% 77,640
28/07/26 $18.26 -3.54% 119,192
27/07/26 $18.93 +1.01% 128,165
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
18.64USD
Average target price
34.20USD
Spread / Average Target
+83.48%

Quarterly revenue - Rate of surprise